Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.

Pharmaceuticals (Basel) · 2023 · PMC10300994 · PMID 37375813

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

possibly significantno p-value reported

This trial, however, was too small to determine infrequent but possibly significant side effects.

also in 649 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.